p57KIP2 methylation as a prognostic biomarker of malignant lymphoma
| Project/Area Number |
22591055
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | National Hospital Organization Nagoya Medical Center |
|---|
Principal Investigator |
NAGAI Hirokazu 独立行政法人国立病院機構(名古屋医療センター臨床研究センター), 臨床研究センター, 部長 (30360811)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 癌 / 悪性リンパ腫 / 予後予測因子 / がん抑制遺伝子 / p57KI2遺伝子 / 予後因子 / p57KIP2 / p57KIP2遺伝子 |
|---|
| Research Abstract |
Biomarkers are critical in the diagnosis and monitoring of diseases. This research was conducted to establish the molecular biomarker for malignant lymphoma. p57KIP2 gene was highly methylated in malignant lymphoma. This methylation was detected in lesions but also in peripheral blood serum DNAs of lymphoma patients. It would be an efficient and convenient marker for lymphoma.
|
Report
(4 results)
Research Products
(39 results)
-
[Journal Article] Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups.2013
Author(s)
Kihara R, Watanabe T, Yano T, Uike N, Okamura S, Kawano F, Hanada S, Sunami K, Inoue N, Sawamura M, Yoshida S, Shimomura T, Kitano K, Kojima Y, Horibe K, Nagai H
-
Journal Title
Int J Hematol.
Volume: 98(1)
Pages: 98-102
Related Report
-
-
-
-
-
-
[Journal Article] Clinical characteristics of humanimmunodeficiency virus-associated Hodgkin lymphoma patients in Japan.2012
Author(s)
Yotsumoto M, Hagiwara S, Ajisawa A, Tanuma J, Uehira T, Nagai H, Fujikawa Y, Maeda S, Kitano K, Arima N, Uno K, Iwai T, Hongo I, Ota Y, Fukutake K, and Okada S
-
Journal Title
Int J Hematol.
Volume: 96(2)
Pages: 247-53
Related Report
-
-
-
-
-
-
[Journal Article] IDEC-C2B8 Study Group. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab : a multicenter phase II study.2011
Author(s)
Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y
-
Journal Title
Cancer Sci.
Volume: 102(9)
Pages: 1698-705
Related Report
-
[Journal Article] Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.2011
Author(s)
Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T
-
Journal Title
Eur J Haematol.
Volume: 86(2)
Pages: 117-23
Related Report
-
-
-
[Journal Article] Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era.2010
Author(s)
Nagai H, Odawara T, Ajisawa A, Hagiwara S, Watanabe T, Uehira T, Uchiumi H, Yotsumoto M, Miyakawa T, Watanabe A, Kambe T, Konishi M, Saito S, Takahama S, Tateyama M, Okada S
-
Journal Title
Eur J Haematol.
Volume: 84(6)
Pages: 499-505
Related Report
-
[Journal Article] The Japanese Bendamustine Lymphoma Study Group. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.2010
Author(s)
Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K
-
Journal Title
Cancer Sci.
Volume: 101(9)
Pages: 2059-64
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Increased Peripheral T Cell Response to EBV-Infected Cells with Frequent Detection of EBV-DNA In Plasma and Viral mRNA In Peripheral B-Cells In Immunocompetent EBV-Positive Diffuse Large B-Cell Lymphoma Patients.2010
Author(s)
Morisima S, Yamamoto K, Kimura H, Iwata S, Kinoshita T, Nagai H, Sugiura I, Tsushita K, Kagami Y, Miyamura K, Kuzushima K, Nakamura S, Morishima Y.
Organizer
52th Annual Meeting of the American Society of Hematology
Place of Presentation
Orland, USA
Related Report
-
